where do we go next with egfr inhibitors?
Published 10 years ago • 59 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
6:37
impressive findings for next-generation egfr inhibitors
-
3:15
how do we make egfr inhibitors work better for patients
-
4:21
how do you help your egfr patients make treatment decisions when their cancers grow?
-
21:41
beyond erlotinib: are second generation egfr inhibitors better or simply newer?
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
7:31
newer egfr inhibitors in nsclc
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
18:06
egfr inhibitors in mutation ( ) patients: current therapeutic strategies in the frontline setting
-
7:12
case based panel discussion - egfr - chemotherapy and egfr inhibitor concurrently or sequentially?
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
21:23
immunotherapy for targeted therapies - what do we know helena yu, md
-
1:25
targeting egfr-positive nsclc with antibody-drug conjugates
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
2:08
research investigates role of antiangiogenic agents and checkpoint inhibitors in egfr nsclc
-
1:04:00
watch drs. jones and pennell discuss the latest in egfr updates - https://bit.ly/egfr_2021
-
5:28
egfr-mutated nsclc; where we are now?
-
4:50
tatton: phase 1b trial of azd9291 for egfr-mutant lung cancer
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
0:43
dr. jackman on overcoming resistance to egfr inhibitors in lung cancer